rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Emergent BioSolutions Inc.

EBS · NYSE

Health CareBiotechnologyNot moving yet

EBS stood above a rising 150-day average in 18 of the last 52 weekly readings, and has been out of that trend for the last 34 weeks. It is 14.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 34
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$1.8M
Officials’ trades on record
13
Institutions holding
185 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 18 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$739K$0$309KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

13 disclosed lines: House 13, Senate 0, executive 0; 3 people.

WhoDidAmountTraded
Steve Cohen House: U.S. House ClerkTN09sold$1k–$15k11 Dec 2024filed 10 Jan 2025
Josh Gottheimer House: U.S. House ClerkNJ05sold$1k–$15k5 Nov 2021filed 13 Dec 2021
Josh Gottheimer House: U.S. House ClerkNJ05bought$1k–$15k18 Oct 2021filed 15 Nov 2021
Josh Gottheimer House: U.S. House ClerkNJ05sold$1k–$15k15 Sep 2021filed 13 Oct 2021
Josh Gottheimer House: U.S. House ClerkNJ05sold$1k–$15k23 Feb 2021filed 10 Mar 2021
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k24 Nov 2020filed 15 Dec 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k30 Jul 2020filed 19 Aug 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k30 Jun 2020filed 17 Jul 2020
Josh Gottheimer House: U.S. House ClerkNJ05bought$1k–$15k26 Jun 2020filed 9 Jul 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k19 Jun 2020filed 17 Jul 2020
Josh Gottheimer House: U.S. House ClerkNJ05bought$1k–$15k15 Jun 2020filed 9 Jul 2020
Steve Cohen House: U.S. House ClerkTN09sold$1k–$15k26 Mar 2020filed 22 Apr 2020

Insiders

Buy orders, 12 months0
Sale orders, 12 months11
Buyers · sellers0 · 6
WhoDidSharesTraded
Donald W. DegolyerDirectorsold17,800at $7.097 Oct 2026filed 7 Oct 2026
Paul Anthony WilliamsSVP, Products Businesssold3,000at $6.531 Oct 2026filed 5 Oct 2026
Paul Anthony WilliamsSVP, Products Businesssold3,000at $8.401 Jul 2026filed 2 Jul 2026
Sujata Tyagi DayalDirectorsold12,781at $8.361 May 2026filed 4 May 2026
Sujata Tyagi DayalDirectorsold980at $8.941 May 2026filed 4 May 2026
Donald W. DegolyerDirectorsold14,527at $8.361 May 2026filed 4 May 2026
Donald W. DegolyerDirectorsold954at $8.961 May 2026filed 4 May 2026
Kathryn C. ZoonDirectorsold16,145at $8.361 May 2026filed 4 May 2026
Kathryn C. ZoonDirectorsold1,057at $8.971 May 2026filed 4 May 2026
Keith KatkinDirectorsold15,481at $8.2830 Apr 2026filed 4 May 2026
Paul Anthony WilliamsSVP, Products Businesssold4,000at $8.441 Apr 2026filed 3 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders185+6 on the quarter
New · exited34 · 26
Reported value$354.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20264,716,599$39.5M+375,137+8.6%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20263,076,646$25.8M+319,488+11.6%
STATE STREET CORPadded · filed 7 Aug 20262,929,238$24.6M+79,537+2.8%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 20262,770,448$23.2M+344,726+14.2%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20262,198,839$18.4M-59,156−2.6%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,337,243$11.2M+64,334+5.1%
CHARLES SCHWAB INVESTMENT MANAGEMENT INCreduced · filed 14 Aug 20261,200,791$10.1M-305,284−20.3%
Sixth Street Partners Management Company, L.P.new · filed 14 Aug 20261,200,791$10.1M+1,200,791
OAK HILL ADVISORS LPunchanged · filed 14 Aug 20261,113,338$9.3M00.0%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20261,072,185$9.0M+540,184+101.5%
31 Mar 2023 – 30 Jun 2026
111147182Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Donald W. DeGolyer Company insiderDirector · last 7 Oct 20260 · 5
Paul Anthony Williams Company insiderSVP, Products Business · last 1 Oct 20260 · 3
Coleen Glessner Company insiderEVP, Quality & Ethics, and CPL · last 8 Jun 20260 · 1
Richard S. Lindahl Company insiderEVP, Chief Financial Officer · last 8 Jun 20261 · 0
William Hartzel Company insiderSVP, Bioservices · last 8 Jun 20260 · 0
Kathryn C. Zoon Company insiderDirector · last 1 May 20260 · 23
Sujata Tyagi Dayal Company insiderDirector · last 1 May 20260 · 2
John D. Fowler Jr. Company insiderDirector · last 30 Apr 20260 · 0
Keith Katkin Company insiderDirector · last 30 Apr 20260 · 2
Marvin L. White Company insiderDirector · last 30 Apr 20260 · 2
Neal Franklin Fowler Company insiderDirector · last 30 Apr 20260 · 1
Ronald Richard Company insiderDirector · last 30 Apr 20260 · 26

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202556.1%
Operating profit marginFY 2025 · to 31 Dec 202513.5%
Free cash flow marginFY 2025 · to 31 Dec 202521.1%
Return on capital employedFY 2025 · to 31 Dec 20258.4%
Cash conversionFY 2025 · to 31 Dec 2025324%
Debt to equityFY 2025 · to 31 Dec 20251.13×
Research spendFY 2025 · to 31 Dec 20257.2%
Share count trendFY 2025 · to 19 Feb 2026-0.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$205.4M
Free cash flowFY 2025 · to 31 Dec 2025$156.8M

Analyst forecasts

No analyst forecasts yet.